AyuVis: AyuVis Research Receives Fast-Track Designation for AVR-48 for the Prevention of Chronic Lung Injury in Preterm Babies

AyuVis Research, Inc., a clinical-stage biopharmaceutical company, has received Fast-Track designation for an investigational new drug - AVR-48 - from... Read More The post AyuVis Research Receives Fast-Track Designation for AVR-48 for the Prevention of Chronic Lung Injury in Preterm Babies appeared first on citybiz.